# Antonio Lacquaniti

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 96 papers | 2,436 citations | 24 h-index | 47 g-index |
| 101 ext. papers | 2,770 ext. citations | 3.9 avg, IF | 4.48 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 96 | Response to: Urine bikunin and kidney involvement in Fabry disease.. *Pediatric Nephrology*, **2022**, 1 | 3.2 | |
| 95 | HMGB-1 and TGF-β1 highlight immuno-inflammatory and fibrotic processes before proteinuria onset in pediatric patients with Alport syndrome. *Journal of Nephrology*, **2021**, 34, 1915-1924 | 4.8 | 2 |
| 94 | Fabry disease and kidney involvement: starting from childhood to understand the future. *Pediatric Nephrology*, **2021**, 1 | 3.2 | 4 |
| 93 | Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy. *Seminars in Dialysis*, **2021**, 34, 183-195 | 2.5 | 1 |
| 92 | Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. *Kidney Research and Clinical Practice*, **2020**, 39, 334-343 | 3.6 | 2 |
| 91 | Acute and chronic kidney disease after pediatric liver transplantation: An underestimated problem. *Clinical Transplantation*, **2020**, 34, e14082 | 3.8 | 2 |
| 90 | Erythropoiesis and chronic kidney disease-related anemia: From physiology to new therapeutic advancements. *Medicinal Research Reviews*, **2019**, 39, 427-460 | 14.4 | 16 |
| 89 | Non-Invasive Imaging for Evaluating Cardiovascular Involvement in Patients with Primary and Lupus Nephritis. *Open Rheumatology Journal*, **2019**, 13, 86-93 | 0.2 | |
| 88 | Convective Dialysis Reduces Mortality Risk: Results From a Large Observational, Population-Based Analysis. *Therapeutic Apheresis and Dialysis*, **2018**, 22, 457-468 | 1.9 | 4 |
| 87 | The Myth of Water and Salt: From Aquaretics to Tenapanor. *Journal of Renal Nutrition*, **2018**, 28, 73-82 | 3 | 5 |
| 86 | Opposite actions of urotensin II and relaxin-2 on cellular expression of fibronectin in renal fibrosis: A preliminary experimental study. *Clinical and Experimental Pharmacology and Physiology*, **2017**, 44, 1069-1071 | 3 | 2 |
| 85 | Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study. *Osteoporosis International*, **2017**, 28, 577-584 | 5.3 | 9 |
| 84 | Renoprotective effect of erythropoietin in zebrafish after administration of gentamicin: an immunohistochemical study for β-catenin and c-kit expression. *Journal of Nephrology*, **2017**, 30, 385-391 | 4.8 | 2 |
| 83 | Persistent left superior vena cava and partially left inferior vena cava: a case report of a dangerous central venous catheterization. *Journal of Vascular Access*, **2017**, 18, e66-e69 | 1.8 | 4 |
| 82 | Salt-water imbalance and fluid overload in hemodialysis patients: a pivotal role of corin. *Clinical and Experimental Medicine*, **2016**, 16, 443-9 | 4.9 | 5 |
| 81 | 3 Tesla-Diffusion Tensor Imaging in Autosomal Dominant Polycystic Kidney Disease: The Nephrologist's Point of View. *Nephron*, **2016**, 134, 73-80 | 3.3 | 7 |
| 80 | Apelin and Copeptin as Biomarkers of Kidney Disease **2016**, 535-556 | | |

| | | | |
|---|---|---|---|
| 79 | Kidney-lung connections in acute and chronic diseases: current perspectives. *Journal of Nephrology*, **2016**, 29, 341-348 | 4.8 | 17 |
| 78 | Kidney disease and psoriasis: novel evidences beyond old concepts. *Clinical Rheumatology*, **2016**, 35, 297-302 | 3.9 | 17 |
| 77 | Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease. *Current Medicinal Chemistry*, **2016**, 23, 1698-707 | 4.3 | 7 |
| 76 | Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology **2016**, 205-227 | | |
| 75 | Renal biopsy: Still a landmark for the nephrologist. *World Journal of Nephrology*, **2016**, 5, 321-7 | 3.6 | 30 |
| 74 | New options for the management of polycystic kidney disease. *Giornale De Techniche Nefrologiche & Dialitiche*, **2016**, 28, 143-152 | 0 | 1 |
| 73 | MP555SALT WATER DISEQUILIBRIUM AND FLUID OVERLOAD IN HEMODYALYSES PATIENTS: A CENTRAL ROLE OF CORIN. *Nephrology Dialysis Transplantation*, **2016**, 31, i525-i525 | 4.3 | |
| 72 | Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. *International Journal of Nephrology and Renovascular Disease*, **2016**, 9, 11-9 | 2.5 | 21 |
| 71 | SP266PREDICTING PROGRESSION IN CKD: CORIN BALANCES HEART AND RENAL SYSTEMS. *Nephrology Dialysis Transplantation*, **2016**, 31, i176-i176 | 4.3 | |
| 70 | Sclerostin levels in uremic patients: a link between bone and vascular disease. *Renal Failure*, **2016**, 38, 759-64 | 2.9 | 13 |
| 69 | Delayed graft function and chronic allograft nephropathy: diagnostic and prognostic role of neutrophil gelatinase-associated lipocalin. *Biomarkers*, **2016**, 21, 371-8 | 2.6 | 11 |
| 68 | Metformin-related lactic acidosis: is it a myth or an underestimated reality?. *Renal Failure*, **2016**, 38, 1560-1565 | 2.9 | 21 |
| 67 | Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. *Journal of Clinical and Translational Endocrinology*, **2016**, 6, 8-14 | 2.4 | 23 |
| 66 | High mobility group box 1 and tumor growth factor □useful biomarkers in pediatric patients receiving peritoneal dialysis. *Renal Failure*, **2016**, 38, 1370-1376 | 2.9 | 5 |
| 65 | Semaphorin 3A serum levels are influenced by haemodialysis: what clinical significance?. *Nephrology*, **2015**, 20, 236-42 | 2.2 | 1 |
| 64 | Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment. *Therapeutic Apheresis and Dialysis*, **2015**, 19, 471-6 | 1.9 | 11 |
| 63 | Pseudotumor Cerebri Syndrome and Renal Diseases in the Pediatric Population. *Journal of Pediatric Neurology*, **2015**, 13, 042-045 | 0.2 | 2 |
| 62 | Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment. *European Journal of Haematology*, **2015**, 94, 404-12 | 3.8 | 23 |

| | | | |
|---|---|---|---|
| 61 | Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection. *Clinical Microbiology and Infection*, **2015**, 21, 368.e1-9 | 9.5 | 23 |
| 60 | Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. *Clinical and Experimental Medicine*, **2015**, 15, 97-105 | 4.9 | 28 |
| 59 | Thalassaemia major and infectious risk: High Mobility Group Box-1 represents a novel diagnostic and prognostic biomarker. *British Journal of Haematology*, **2015**, 171, 130-6 | 4.5 | 4 |
| 58 | New available biomarkers to face a worldwide emergency: The childhood obesity. *Journal of Pediatric Biochemistry*, **2015**, 04, 139-143 | | |
| 57 | Overview of Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker in Nephrology **2015**, 1-24 | | |
| 56 | Apelin and Copeptin as Biomarkers of Kidney Disease **2015**, 1-22 | | |
| 55 | Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein. *Medicinal Research Reviews*, **2014**, 34, 77-105 | 14.4 | 38 |
| 54 | High-mobility group box 1 (HMGB1) in childhood: from bench to bedside. *European Journal of Pediatrics*, **2014**, 173, 1123-36 | 4.1 | 26 |
| 53 | LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response. *Diabetes and Metabolism*, **2014**, 40, 224-8 | 5.4 | 5 |
| 52 | Serum levels of Apelin-36 are decreased in older hospitalized patients with heart failure. *European Geriatric Medicine*, **2014**, 5, 242-245 | 3 | 3 |
| 51 | Vitamin D intoxication in two brothers: be careful with dietary supplements. *Journal of Pediatric Endocrinology and Metabolism*, **2014**, 27, 763-7 | 1.6 | 18 |
| 50 | Proteinuric effect of transcranial magnetic stimulation in healthy subjects and diabetic patients with stage 3-4 CKD. *Nephrology Dialysis Transplantation*, **2014**, 29, 573-9 | 4.3 | 4 |
| 49 | Emerging markers of cachexia predict survival in cancer patients. *BMC Cancer*, **2014**, 14, 828 | 4.8 | 35 |
| 48 | From water to aquaretics: a legendary route. *Cellular Physiology and Biochemistry*, **2014**, 33, 1369-88 | 3.9 | 10 |
| 47 | Does erythropoietin always win?. *Current Medicinal Chemistry*, **2014**, 21, 849-54 | 4.3 | 9 |
| 46 | "Normoalbuminuric" diabetic nephropathy: tubular damage and NGAL. *Acta Diabetologica*, **2013**, 50, 935-42 | 3.9 | 56 |
| 45 | Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease. *Peptides*, **2013**, 49, 1-8 | 3.8 | 24 |
| 44 | High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children. *European Journal of Endocrinology*, **2013**, 168, 631-8 | 6.5 | 56 |

| | | | |
|---|---|---|---|
| 43 | Prolactin in obese children: a bridge between inflammation and metabolic-endocrine dysfunction. *Clinical Endocrinology*, **2013**, 79, 537-44 | 3.4 | 33 |
| 42 | Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy?. *Radiology*, **2013**, 267, 86-93 | 20.5 | 38 |
| 41 | Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. *European Journal of Endocrinology*, **2013**, 169, 785-93 | 6.5 | 18 |
| 40 | Impact of diabetes on cognitive impairment and disability in elderly hospitalized patients with heart failure. *Geriatrics and Gerontology International*, **2013**, 13, 1035-42 | 2.9 | 12 |
| 39 | Neutrophil gelatinase-associated lipocalin (NGAL) and endothelial progenitor cells (EPCs) evaluation in aortic aneurysm repair. *Current Vascular Pharmacology*, **2013**, 11, 1001-10 | 3.3 | 5 |
| 38 | Neutrophil gelatinase-associated lipocalin in peritoneal dialysis reflects status of peritoneum. *Journal of Nephrology*, **2013**, 26, 1151-9 | 4.8 | 3 |
| 37 | Modifications in relaxinB serum levels during acetate-free biofiltration (AFB): only a new biomarker?. *Italian Journal of Anatomy and Embryology*, **2013**, 118, 98-9 | | 3 |
| 36 | Hydrocarbons and kidney damage: potential use of neutrophil gelatinase-associated lipocalin and sister chromatide exchange. *American Journal of Nephrology*, **2012**, 35, 271-8 | 4.6 | 11 |
| 35 | Real-time monitoring of breath ammonia during haemodialysis: use of ion mobility spectrometry (IMS) and cavity ring-down spectroscopy (CRDS) techniques. *Nephrology Dialysis Transplantation*, **2012**, 27, 2945-52 | 4.3 | 51 |
| 34 | A biotechnological T-shirt monitors the patientB heart during hemodialysis. *Renal Failure*, **2012**, 34, 818-20 | 2.9 | |
| 33 | NGAL as an early biomarker of kidney disease in Joubert syndrome: three brothers compared. *Renal Failure*, **2012**, 34, 495-8 | 2.9 | 8 |
| 32 | Apelin, plasmatic osmolality and hypotension in dialyzed patients. *Blood Purification*, **2012**, 33, 317-23 | 3.1 | 18 |
| 31 | Fibrosis, regeneration and cancer: what is the link?. *Nephrology Dialysis Transplantation*, **2012**, 27, 21-7 | 4.3 | 24 |
| 30 | NGAL is a precocious marker of therapeutic response. *Current Pharmaceutical Design*, **2011**, 17, 844-9 | 3.3 | 14 |
| 29 | From chronic kidney disease to transplantation: the roles of obestatin. *Regulatory Peptides*, **2011**, 171, 48-52 | | 5 |
| 28 | Levels of neutrophil gelatinase-associated lipocalin in 2 patients with crush syndrome after a mudslide. *American Journal of Critical Care*, **2011**, 20, 405-9 | 1.7 | 3 |
| 27 | Obestatin: a new element for mineral metabolism and inflammation in patients on hemodialysis. *Kidney and Blood Pressure Research*, **2011**, 34, 104-10 | 3.1 | 10 |
| 26 | Obestatin: an interesting but controversial gut hormone. *Annals of Nutrition and Metabolism*, **2011**, 59, 193-9 | 4.5 | 39 |

| | | | |
|---|---|---|---|
| 25 | Erythropoietin and the truths of science. *Journal of Nephrology*, **2011**, 24, 564-8 | 4.8 | 6 |
| 24 | From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. *European Journal of Clinical Investigation*, **2010**, 40, 273-6 | 4.6 | 74 |
| 23 | Neutrophil gelatinase-associated lipocalin levels in chronic haemodialysis patients. *Nephrology*, **2010**, 15, 23-6 | 2.2 | 23 |
| 22 | Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. *Kidney and Blood Pressure Research*, **2010**, 33, 100-10 | 3.1 | 22 |
| 21 | Both IL-1 and TNF- regulate NGAL expression in polymorphonuclear granulocytes of chronic hemodialysis patients. *Mediators of Inflammation*, **2010**, 2010, 613937 | 4.3 | 12 |
| 20 | Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. *Cancer Letters*, **2010**, 288, 10-6 | 9.9 | 129 |
| 19 | Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 642-7 | 2.8 | 15 |
| 18 | Neutrophil Gelatinase-Associated Lipocalin Levels in Patients With Crohn Disease Undergoing Treatment With Infliximab. *Journal of Investigative Medicine*, **2010**, 58, 569-571 | 2.9 | 33 |
| 17 | Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. *Journal of Investigative Medicine*, **2010**, 58, 569-71 | 2.9 | 13 |
| 16 | Genomic damage in endothelial progenitor cells from uremic patients in hemodialysis. *Journal of Nephrology*, **2010**, 23, 328-34 | 4.8 | 6 |
| 15 | Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle?. *Medical Science Monitor*, **2010**, 16, RA131-5 | 3.2 | 27 |
| 14 | Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 337-44 | 6.9 | 350 |
| 13 | Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. *Nephrology Dialysis Transplantation*, **2009**, 24, 3398-403 | 4.3 | 39 |
| 12 | The erythropoietin and regenerative medicine: a lesson from fish. *European Journal of Clinical Investigation*, **2009**, 39, 993-9 | 4.6 | 9 |
| 11 | Perioperative iloprost and endothelial progenitor cells in uremic patients with severe limb ischemia undergoing peripheral revascularization. *Journal of Surgical Research*, **2009**, 157, e129-35 | 2.5 | 15 |
| 10 | Malnutrition in the elderly patient on dialysis. *Renal Failure*, **2009**, 31, 239-45 | 2.9 | 27 |
| 9 | Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. *Kidney and Blood Pressure Research*, **2009**, 32, 91-8 | 3.1 | 131 |
| 8 | Neutrophil gelatinase-associated lipocalin in the intensive care unit: time to look beyond a single, threshold-based measurement?. *Critical Care Medicine*, **2009**, 37, 2864; author reply 2864-5 | 1.4 | 4 |

| | | | |
|---|---|---|---|
| 7 | Regenerative medicine: does Erythropoietin have a role?. *Current Pharmaceutical Design*, **2009**, 15, 2026-36 | 3.9 | 10 |
| 6 | Neutrophil gelatinase-associated lipocalin in the intensive care unit: Time to look beyond a single, threshold-based measurement?. *Critical Care Medicine*, **2009**, 37, 2864 | 1.4 | |
| 5 | Down with the erythropoietin. Long live the erythropoietin!. *Current Drug Targets*, **2009**, 10, 1028-32 | 3 | 8 |
| 4 | Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. *American Journal of Kidney Diseases*, **2008**, 52, 595-605 | 7.4 | 382 |
| 3 | Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. *Kidney and Blood Pressure Research*, **2008**, 31, 274-9 | 3.1 | 60 |
| 2 | Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. *Kidney and Blood Pressure Research*, **2008**, 31, 255-8 | 3.1 | 94 |
| 1 | Dialysis and the elderly: an underestimated problem. *Kidney and Blood Pressure Research*, **2008**, 31, 330-6 | 3.1 | 29 |